Polarityte (NASDAQ:PTE) has been given a $65.00 price target by equities research analysts at Cantor Fitzgerald in a research report issued on Monday, Stock Target Advisor reports. The firm currently has a “buy” rating on the stock.

Several other brokerages also recently commented on PTE. Zacks Investment Research raised shares of Polarityte from a “sell” rating to a “hold” rating in a research note on Tuesday, March 26th. Evercore ISI began coverage on Polarityte in a research note on Wednesday, March 20th. They issued an “outperform” rating and a $26.00 target price on the stock. Piper Jaffray Companies set a $30.00 price target on Polarityte and gave the company a “buy” rating in a report on Monday, March 18th. Northland Securities restated a “buy” rating and set a $50.00 price target on shares of Polarityte in a report on Monday, March 18th. Finally, ValuEngine lowered Polarityte from a “buy” rating to a “hold” rating in a research report on Tuesday, February 5th. One analyst has rated the stock with a sell rating, two have issued a hold rating and five have issued a buy rating to the company. The company has an average rating of “Buy” and a consensus price target of $34.33.

Shares of PTE stock opened at $10.51 on Monday. The stock has a market cap of $234.29 million, a P/E ratio of -2.16 and a beta of 1.48. Polarityte has a 1-year low of $9.45 and a 1-year high of $41.22. The company has a debt-to-equity ratio of 0.01, a current ratio of 13.80 and a quick ratio of 13.76.

Polarityte (NASDAQ:PTE) last announced its quarterly earnings results on Monday, January 14th. The company reported ($0.96) EPS for the quarter, topping the Zacks’ consensus estimate of ($1.02) by $0.06. The business had revenue of $1.13 million for the quarter, compared to analysts’ expectations of $0.80 million. Polarityte had a negative return on equity of 258.52% and a negative net margin of 4,259.44%. As a group, equities research analysts expect that Polarityte will post -4.14 EPS for the current fiscal year.

About Polarityte

PolarityTE, Inc, a biotechnology and regenerative biomaterials company, focuses on discovering, designing, and developing a range of regenerative tissue products and biomaterials for the fields of medicine, biomedical engineering, and material sciences in the United States. The company operates in two segments, Regenerative Medicine and Contract Services.

See Also: Hedge Funds – Risk or Reward?

Analyst Recommendations for Polarityte (NASDAQ:PTE)

Receive News & Ratings for Polarityte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Polarityte and related companies with MarketBeat.com's FREE daily email newsletter.